Biogen and Eisai’s future Phase III trial of Alzheimer’s disease (AD) drug BAN2401, whose development has been closely watched by investors and the...
Read More...
The post Biogen/Eisai’s BAN2401 Alzheimer’s data supports APOE4+ patient inclusion in Phase III appeared first on Pharmaceutical Technology.